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Conclusion: We measured neutron spectra and calculated 
neutron dose equivalents for a clinical treatment for a single 
gantry proton system, whose use and planned installations 
have recently increased. Data reported here are consistent 
with dose equivalents reported for CSI carried out with other 
proton therapy beamlines. 
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Purpose or Objective: More than half of cancer patients 
receive radiotherapy for radical or palliative purposes. 
Increasing survival rates in cancer patients make it important 
to study late side-effects, including secondary radiation-
induced cancers. Although a number of predictive models 
exist, the absolute accuracy of these models in the 
radiotherapy dose range is limited partly due to scarcity of 
data and partly by extrapolation beyond historical data 
bounds. The aim of this work is to investigate conversion of 
malignant induction probabilities, which provide useful 
relative risk estimates, into absolute life time attributable 
risk estimates (LAR) and excess absolute risk (EAR) by 
calibrating and benchmarking our models using published 
outcome data. 
 
Material and Methods: An in-house modelling tool, which 
calculates voxelwise risk estimates from patient-specific 3D 
dose distributions, was modified to generate linear-no-
threshold (LNT) model-based risk estimates for the whole 
body and per organ using organ-equivalent dose. Second 
cancer risk was calculated for uniform whole-body exposure 
of 0.1 Gy for comparison with tabulated BIER VII data. Model 
parameters initially used were taken from existing published 
reports for the relevant models. The calculated LAR was then 
compared to the BIER VII results and the linear coefficient, λ, 
was adjusted to make the model prediction better match the 
BEIR VII result. A similar calibration of parameters was then 
performed for the linear quadratic (LQ) and linear model 
(LIN) malignant induction coefficients. EAR was calculated 
for a dose range to compare results with published data.  
 
Results: After calibration, calculations of LAR for single 
uniform exposure of 0.1 Gy produced a value of 837 cases per 
100,000 for an exposure at age of 40, in comparison to 824 
according to BIER VII report. Averaging over ages at exposure 
of 20 to 80 produced a value within 5% of the BIER VII report. 
Calculations of EAR for a dose range relevant to RT of 1-6 Gy 
using the LIN model were always within the range of 
uncertainty due to differences in RBE neutron value in the 
independent published Hodgkin Lymphoma data (Schneider et 
al, 2008).  
 
 
 
Conclusion: These results show that our models can produce 
absolute LAR estimates for secondary cancer which are 
consistent with the values reported in the BEIR VII report for 
uniform irradiation to 0.1Gy. The comparison of our results of 
EAR using LIN model to published data showed agreement 
with independent published data of HL.  
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Purpose or Objective: There is increased use of proton 
therapy in pediatric cancer patients. In treatment planning, 
neutrons produced in the treatment delivery system and the 
patient are usually ignored and not documented. The goal of 
this ongoing project is to develop and establish a system for 
measuring and simulating 3D neutron and gamma radiation 
fields of passively scattered and actively scanned proton 
beams using representative clinical proton fields impinging on 
tissue-equivalent phantom materials. Eventually this should 
lead to a standardized approach for calculating organ neutron 
doses in paediatric proton patients. 
 
Material and Methods: The neutron dosimetry consists of 
neutron and gamma fluence measurements with an array of 
three organic scintillators positioned 70-80 cm lateral to 
blocks of tissue equivalent materials (soft tissue and compact 
